Combined PET/MRI: One step further in multimodality imaging

Trends in Molecular Medicine

Volumn 16, Issue 11, 2010, Pages 508-515

  Sauter, Alexander W ^a   Wehrl, Hans F ^a   Kolb, Armin ^a   Judenhofer, Martin S ^a   Pichler, Bernd J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTER ASSISTED TOMOGRAPHY; HUMAN; MEDICAL TECHNOLOGY; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY;

ANIMALIA;

EID: 78049234611     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2010.08.003     Document Type: Review

References (71)

1. Riesz P.B. The life of Wilhelm Conrad Roentgen. AJR Am. J. Roentgenol. 1995, 165:1533-1537.
2. Cannon W.B. The Movements of the Intestines studied by Means of the Rontgen Rays. J. Med. Res. 1902, 7:72-75.
3. Tselos G.D. New Jersey's Thomas Edison and the fluoroscope. N. J. Med. 1995, 92:731-733.
4. Becquerel J., Crowther J.A. Discovery of radioactivity. Nature 1948, 161:609.
5. Mould R.F. The discovery of radium in 1898 by Maria Sklodowska-Curie (1867-1934) and Pierre Curie (1859-1906) with commentary on their life and times. Br. J. Radiol. 1998, 71:1229-1254.
6. Leitha T. Nuclear medicine: proof of principle for targeted drugs in diagnosis and therapy. Curr. Pharm. Des. 2009, 15:173-187.
7. Donald I. On launching a new diagnostic science. Am. J. Obstet. Gynecol. 1969, 103:609-628.
8. Anger H.O. Use of a gamma-ray pinhole camera for in vivo studies. Nature 1952, 170:200-201.
9. Kuhl D.E., Edwards R.Q. Cylindrical and Section Radioisotope Scanning of the Liver and Brain. Radiology 1964, 83:926-936.
10. Levine D.A. A class of biomathematical models for radiology imaging. Comput. Biol. Med. 1972, 2:257-265.
11. Hounsfield G.N. Computerized transverse axial scanning (tomography). 1. Description of system. Br. J. Radiol. 1973, 46:1016-1022.
12. Phelps M.E., et al. Application of annihilation coincidence detection to transaxial reconstruction tomography. J. Nucl. Med. 1975, 16:210-224.
13. Ter-Pogossian M.M., et al. A positron-emission transaxial tomograph for nuclear imaging (PETT). Radiology 1975, 114:89-98.
14. Lauterbur P.C. Progress in n.m.r. zeugmatography imaging. Philos Trans. R. Soc. Lond. B. Biol. Sci. 1980, 289:483-487.
15. Mansfield P., Maudsley A.A. Line scan proton spin imaging in biological structures by NMR. Phys. Med. Biol. 1976, 21:847-852.
16. Davies J.R., et al. Molecular and metabolic imaging of atherosclerosis. J. Nucl. Med. 2004, 45:1898-1907.
17. Kiessling F., et al. Functional and molecular ultrasound imaging: concepts and contrast agents. Curr. Med. Chem. 2009, 16:627-642.
18. Margolis D.J., et al. Molecular imaging techniques in body imaging. Radiology 2007, 245:333-356.
19. Hamamura M.J., et al. Initial Investigation of preclinical integrated SPECT and MR imaging. Technol. Cancer Res. Treat. 2010, 9:21-28.
20. Thayer D., et al. Dual-contrast dynamic MRI-DOT for small animal imaging. Technol. Cancer Res. Treat. 2010, 9:61-70.
21. Barber W.C., et al. Combined fluorescence and X-ray tomography for quantitative in vivo detection of fluorophore. Technol. Cancer Res. Treat. 2010, 9:45-52.
22. Davis S.C., et al. MRI-coupled fluorescence tomography quantifies EGFR activity in brain tumors. Acad. Radiol. 2010, 17:271-276.
23. Jemal A., et al. Cancer statistics, 2009. CA. Cancer J. Clin. 2009, 59:225-249.
24. Heckl S., et al. Molecular imaging: Bridging the gap between neuroradiology and neurohistology. Histol. Histopathol. 2004, 19:651-668.
25. Higuchi T., et al. Imaging of angiogenesis in cardiology. Eur. J. Nucl. Med. Mol. Imaging. 2007, 34(Suppl 1):S9-S19.
26. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
27. Tennant D.A., et al. Metabolic transformation in cancer. Carcinogenesis 2009, 30:1269-1280.
28. Trosko J.E., et al. Ignored hallmarks of carcinogenesis: stem cells and cell-cell communication. Ann. N. Y. Acad. Sci. 2004, 1028:192-201.
29. Desar I.M., et al. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat. Rev. 2009, 35:309-321.
30. Jadvar H., et al. 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J. Nucl. Med. 2009, 50:1820-1827.
31. Kinahan P.E., et al. Dual energy CT attenuation correction methods for quantitative assessment of response to cancer therapy with PET/CT imaging. Technol. Cancer Res. Treat. 2006, 5:319-327.
32. Shields A.F., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat. Med. 1998, 4:1334-1336.
33. Belt J.A., et al. Nucleoside transport in normal and neoplastic cells. Adv. Enzyme Regul. 1993, 33:235-252.
34. Kong X.B., et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine. Antimicrob. Agents Chemother. 1992, 36:808-818.
35. Reske S.N., Deisenhofer S. Is 3'-deoxy-3'-(18)F-fluorothymidine a better marker for tumour response than (18)F-fluorodeoxyglucose?. Eur. J. Nucl. Med. Mol. Imaging 2006, 33(Suppl 1):38-43.
36. Blankenberg F.G., et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6349-6354.
37. Schellenberger E.A., et al. Annexin V-CLIO: a nanoparticle for detecting apoptosis by MRI. Acad. Radiol. 2002, 9(Suppl 2):S310-311.
38. Guo Y., et al. Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J. Magn. Reson. Imaging 2002, 16:172-178.
39. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285:1182-1186.
40. Choyke P.L., et al. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging 2003, 17:509-520.
41. Murukesh N., et al. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br. J. Cancer 2010, 102:8-18.
42. Turkbey B., et al. Imaging of tumor angiogenesis: functional or targeted?. AJR Am. J. Roentgenol. 2009, 193:304-313.
43. Tofts P.S., et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J. Magn. Reson. Imaging 1999, 10:223-232.
44. Hentschel M., et al. Analysis of blood flow and glucose metabolism in mammary carcinomas and normal breast: a H2(15)O PET and 18F-FDG PET study. Nucl. Med. Commun. 2007, 28:789-797.
45. Longo R., Gasparini G. Anti-VEGF therapy: the search for clinical biomarkers. Expert Rev. Mol. Diagn. 2008, 8:301-314.
46. Kowanetz M., Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin. Cancer Res. 2006, 12:5018-5022.
47. Beer A.J., et al. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin. Cancer Res. 2006, 12:3942-3949.
48. Zheng Q.H., et al. Comparative studies of potential cancer biomarkers carbon-11 labeled MMP inhibitors (S)-2-(4'-[11C]methoxybiphenyl-4-sulfonylamino)-3-methylbutyric acid and N-hydroxy-(R)-2-[[(4'-[11C]methoxyphenyl)sulfonyl]benzylamino]-3-methylbut anamide. Nucl. Med. Biol. 2004, 31:77-85.
49. Haubner R., et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001, 61:1781-1785.
50. Schmieder A.H., et al. Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn. Reson. Med. 2005, 53:621-627.
51. Bedrosian I., et al. 99mTc-human serum albumin: an effective radiotracer for identifying sentinel lymph nodes in melanoma. J. Nucl. Med. 1999, 40:1143-1148.
52. Harisinghani M.G., et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 2003, 348:2491-2499.
53. Jacobson O., et al. 64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4. Bioorg. Med. Chem. 2009, 17:1486-1493.
54. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
55. Ganapathy V., et al. Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol. Ther. 2009, 121:29-40.
56. Ishiwata K., et al. A comparative study on protein incorporation of L-[methyl-3H]methionine. L-[1-14C]leucine and L-2-[18F]fluorotyrosine in tumor bearing mice. Nucl. Med. Biol. 1993, 20:895-899.
57. Jacobs A.H., et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J. Nucl. Med. 2005, 46:1948-1958.
58. Vaupel P., et al. Hypoxia in breast cancer: role of blood flow, oxygen diffusion distances, and anemia in the development of oxygen depletion. Adv. Exp. Med. Biol. 2005, 566:333-342.
59. Rajendran J.G., Krohn K.A. Imaging hypoxia and angiogenesis in tumors. Radiol. Clin. North Am. 2005, 43:169-187.
60. Padhani A.R. Where are we with imaging oxygenation in human tumours?. Cancer Imaging 2005, 5:128-130.
61. Kurhanewicz J., et al. Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia 2000, 2:166-189.
62. Klonisch T., et al. Cancer stem cell markers in common cancers - therapeutic implications. Trends Mol. Med. 2008, 14:450-460.
63. Hung S.C., et al. Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive in vivo positron emission tomography imaging. Clin. Cancer Res. 2005, 11:7749-7756.
64. Spitz M.R., Bondy M.L. The evolving discipline of molecular epidemiology of cancer. Carcinogenesis 2010, 31:127-134.
65. Cherry S.R. In vivo molecular and genomic imaging: new challenges for imaging physics. Phys. Med. Biol. 2004, 49:R13-48.
66. Wehrl H.F., et al. Pre-clinical PET/MR: technological advances and new perspectives in biomedical research. Eur. J. Nucl. Med. Mol. Imaging 2009, 36(Suppl 1):S56-68.
67. Cho Z.H., et al. A fusion PET-MRI system with a high-resolution research tomograph-PET and ultra-high field 7.0 T-MRI for the molecular-genetic imaging of the brain. Proteomics 2008, 8:1302-1323.
68. Hofmann M., et al. MRI-based attenuation correction for PET/MRI: a novel approach combining pattern recognition and atlas registration. J. Nucl. Med. 2008, 49:1875-1883.
69. Martinez-Moller A., et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J. Nucl. Med. 2009, 50:520-526.
70. Judenhofer M.S., et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat. Med. 2008, 14:459-465.
71. Shao Y., et al. Simultaneous PET and MR imaging. Phys. Med. Biol. 1997, 42:1965-1970.